<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02884180</url>
  </required_header>
  <id_info>
    <org_study_id>SM1-DHAG-2016</org_study_id>
    <secondary_id>2016-002769-72</secondary_id>
    <nct_id>NCT02884180</nct_id>
  </id_info>
  <brief_title>DEXRAR: DEXamethasone in Revision ARthroplasty</brief_title>
  <acronym>DEXRAR</acronym>
  <official_title>DEXRAR: DEXamethasone in Revision ARthroplasty: A Randomised, Blinded, 2-group Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel HÃ¤gi-Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naestved Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial name: DEXRAR: Dexamethasone in revision arthroplasty: A randomised, blinded, 2-group
      clinical trial

      Trial acronym: DEXRAR

      Background: Effective postoperative pain management is essential for the well-being and
      rehabilitation of the surgical patient. No &quot;gold standard&quot; exists for pain treatment after
      revision total knee arthroplasty (TKA) and combinations of different medications are used
      with virtually no evidence for combined analgesic efficacy.

      Objectives: The objective is to investigate the analgesic effect and safety of dexamethasone
      as a single dose after revision-TKA in combination with paracetamol, ibuprofen and local
      infiltration analgesia

      Intervention: The patients are randomised into to groups: A) 24 mg dexamethasone i.v. B)
      isotonic saline i.v.

      Design and trial size: Placebo controlled, parallel 2-group trial with adequate centralised
      computer-generated allocation sequence and allocation concealment with block size of 12.
      Blinding of assessor, investigator, caregivers and patients.

      Sample size: 108 eligible patients are needed to detect a difference of 11,3 mg morphine for
      the first 24 h postoperatively with a standard deviation of 20 mg, a type 1 error rate of
      0,05 and a type 2 error rate of 0,20.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Morphine consumption the first 24 hours postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Total need for morphine for the first 24 hours postoperatively administered as both patient controlled analgesia (PCA) and supplemental morphine administered at the post-anaesthesia unit the first hour postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain during movement at 6 hours postoperatively (visual analogue scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) with active 45 degrees flexion of the knee at 6 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during movement at 24 hours postoperatively (visual analogue scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) with active 45 degrees flexion of the knee at 24 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest at 6 hours postoperatively (visual analogue scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) at rest at 6 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest at 24 hours postoperatively (visual analogue scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Pain scores (visual analogue scale (VAS)) at rest at 24 hours postoperatively. No pain = 0; worst imaginable pain = 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and go test</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Time in seconds, for standing up from a chair, walking 3 meters, turning around, walking back to the chair and sit down again</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>0 - 24 hours postoperatively</time_frame>
    <description>Number of patients with one or more adverse events in the intervention period (0-24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea at 6 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Level of nausea at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea at 24 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of nausea at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting the first 24 hours postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Number of vomiting episodes (0-24 hours) measured in the periods 0-6 and 6-24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizziness at 6 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Level of dizziness at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dizziness at 24 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of dizziness at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation at 6 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Level of sedation at 6 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation at 24 hours postoperatively (Verbal rating scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of sedation at 24 hours postoperatively. Verbal rating scale: none, mild, moderate or severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-emetic treatment the first 24 hours postoperatively</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Consumption of ondansetron in the period 0-24 hours postoperatively</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of sleep (Verbal rating scale)</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of quality of sleep. Verbal rating scale: very bad, fairly bad, fairly good, very good</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood sugar level at 6 hours postoperatively</measure>
    <time_frame>6 hours postoperatively</time_frame>
    <description>Level of blood sugar af 6 hours postoperatively in mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood sugar level at 24 hours postoperatively</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Level of blood sugar at 24 hours postoperatively in mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with need for antibiotic treatment and/or reoperation within 90 days</measure>
    <time_frame>0 - 90 days postoperatively</time_frame>
    <description>Number of patients with need for antibiotic treatment and/or reoperation within 90 days after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>0-90 days postoperatively</time_frame>
    <description>Serious adverse events (SAE), including death, within 90 days after surgery defined as SAE (according to International Conference on Harmonization (ICH) - good clinical practice (GCP) - guidelines) except &quot;prolongation of hospitalisation&quot;</description>
  </other_outcome>
  <other_outcome>
    <measure>Days alive and outside hospital within 90 days after surgery</measure>
    <time_frame>0-90 days postoperatively</time_frame>
    <description>Days alive and outside hospital within 90 days after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>Before surgery</time_frame>
    <description>Oxford Knee Score (OKS) before surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>6 month postoperatively</time_frame>
    <description>Oxford Knee Score (OKS) 6 month after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>12 month postoperatively</time_frame>
    <description>Oxford Knee Score (OKS) 12 month after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>Before surgery</time_frame>
    <description>EuroQol five dimensions 5 point Lipert scale (EQ-5D-5L) before surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>6 month postoperatively</time_frame>
    <description>EuroQol five dimensions 5 point Lipert scale (EQ-5D-5L) 6 month after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>12 month postoperatively</time_frame>
    <description>EuroQol five dimensions 5 point Lipert scale (EQ-5D-5L) 12 month after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>Before surgery</time_frame>
    <description>Short Form 36 (SF-36) before surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>6 month postoperatively</time_frame>
    <description>Short Form 36 (SF-36) 6 month after surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of live, function</measure>
    <time_frame>12 month postoperatively</time_frame>
    <description>Short Form 36 (SF-36) 12 month after surgery</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 24 mg i.v. after start of anaesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline isotonic i.v. after start of anaesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>A dose of 24 mg dexamethasone given after start of anaesthesia</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline isotonic</intervention_name>
    <description>A dose of 6 ml of isotonic saline given after start of anaesthesia</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for unilateral, revision-TKA: Total and major partial revisions were
             included, i.e. revisions including the femoral and/or the tibial component(s).

          -  Age &gt; 18

          -  American Society of Anesthesiologists (ASA) physical status classification system ASA
             1- 3.

          -  Body mass index (BMI) &gt; 18 and &lt; 45

          -  Women in the fertile age (i.e. until one year after menopause) must have negative
             urine human chorionic gonadotropin (HCG) pregnancy test

          -  Patients who gave their written informed consent to participating in the trial after
             having fully understood the contents of the protocol and restrictions.

        Exclusion Criteria:

          -  Patients who cannot cooperate with the trial.

          -  Concomitant participation in another trial involving medication

          -  Patients who cannot understand or speak Danish.

          -  Patients with allergy to medicines used in the trial.

          -  Patients with daily use of methadone.

          -  Contraindications against NSAID, for example previous ulcer, heart failure, liver
             failure, or renal failure (eGRF &lt; 60 ml/kg/1,73m2), known thrombocytopenia (&lt;100
             mia/L)

          -  Patients suffering from alcohol and/or drug abuse - based on the investigator's
             judgement.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel HÃ¤gi-Pedersen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anaesthesiology, NÃ¦stved Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel HÃ¤gi-Pedersen, MD</last_name>
    <phone>+4556514792</phone>
    <email>dhag@regionsjaelland.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>NÃ¦stved Hospital</name>
      <address>
        <city>NÃ¸stved</city>
        <state>Region Zealand</state>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel HÃ¤gi-Pedersen, MD</last_name>
      <phone>+4556514792</phone>
      <email>dhag@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Daniel HÃ¤gi-Pedersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Naestved Hospital</investigator_affiliation>
    <investigator_full_name>Daniel HÃ¤gi-Pedersen</investigator_full_name>
    <investigator_title>Head of research, consultant</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Arthroplasty, Replacement, Knee</keyword>
  <keyword>Revision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

